Polygenic risk vectors (PRV) improve genetic risk stratification for cardio-metabolic diseases

Ruowang Li, Xinyuan Zhang, Binglan Li, QiPing Feng, Leah C. Kottyan, Yuan Luo, Konrad Teodor Sawicki, Atlas Khan, Nita Limdi, Megan J. Puckelwartz, Wei‐Qi Wei, Chunhua Weng, Yong Chen, Marylyn D. Ritchie, Jason H. MooremedRxiv 2022 · DOI

Abstract

Accurate disease risk stratification is essential for personalized prevention and treatment. While Polygenic Risk Scores (PRS) aggregate effects from numerous single nucleotide polymorphisms (SNPs), they typically rely on a one-dimensional additive model. This study introduces the Polygenic Risk Vector (PRV), a multi-dimensional approach that incorporates additive and non-additive genetic effects. Using data from the UK Biobank (UKBB) and the eMERGE Network, we demonstrate that combining additive and dominant PRS models significantly improves risk stratification for cardio-metabolic diseases like Type 2 Diabetes and hypertension, particularly for individuals in high-risk groups.

Introduction

Genome-wide association studies (GWAS) have identified thousands of genetic markers associated with complex diseases. Polygenic Risk Scores (PRS) translate this information into a clinical tool by aggregating these markers into a single value representing an individual's genetic liability. However, most PRS methods assume an additive model, where each risk allele increases risk linearly. This simplification ignores non-additive effects like dominance or recessivity, potentially losing critical information for identifying high-risk individuals.

Methods

The researchers developed a multi-dimensional Polygenic Risk Vector (PRV) framework consisting of three main stages: Development, Optimization, and Validation.

The PRV workflow: Development, Optimization, and Validation.

Multi-Model Scoring

Instead of a single score, three separate PRSs are calculated for each individual based on different genetic architectures: Additive, Dominant, and Recessive. The coding for these models varies based on the presence of the minor allele (a).

SNP allele coding for additive, dominant, and recessive models.

Risk Surface Construction and Tuning

The scores are mapped onto a multi-dimensional "risk space." For a 2D PRV (e.g., Additive + Dominant), a grid is created where each cell represents a combination of percentiles for both scores. Using a training dataset, actual disease prevalence is calculated within each grid cell. A grid search then identifies the optimal combinations of scores that define "high-risk" and "low-risk" groups.

Datasets

  • UK Biobank (UKBB): Data from ~500,000 individuals was used for development (70% training, 30% tuning).
  • eMERGE Network (Phase III): An independent validation set of ~70,808 individuals linked to Electronic Health Records (EHR) from 11 US sites was used to test real-world generalizability.

Key Insights and Results

  • Non-Redundant Information: Although Additive and Dominant scores are correlated, they provide distinct information. The "risk contours" on 2D maps are non-linear, allowing for further stratification of individuals with identical additive scores.
  • Superior Stratification: For both Type 2 Diabetes (T2D) and hypertension, the 2D PRV (Additive + Dominant) consistently outperformed the standard 1D additive PRS. In the eMERGE validation set, the PRV identified high-risk groups with significantly higher Odds Ratios (OR) for disease enrichment compared to single-model scores.
  • The "Tail" Matters Most: The PRV shows the most significant improvement at the extreme high end of the risk distribution, which is the most clinically relevant group for preventative interventions.
  • Recessive Model Limitations: For T2D and hypertension, the recessive PRS provided negligible predictive value, suggesting these traits are primarily driven by additive and dominant effects.

Discussion and Future Work

While promising, the study focused on individuals of European ancestry to ensure consistency across datasets. Future work must validate PRVs in diverse populations to ensure equitable clinical utility. Additionally, integrating PRVs with clinical factors (age, BMI) is necessary to provide absolute risk probabilities. Future refinements could also include advanced Linkage Disequilibrium (LD) handling for SNP selection to further refine the accuracy of the individual scores within the vector.

Summary updated

Abstract

1. Abstract Accurate disease risk stratification can lead to more precise and personalized prevention and treatment of diseases. As an important component to disease risk, genetic risk factors can be utilized as an early and stable predictor for disease onset. Recently, the polygenic risk score (PRS) method has combined the effects from hundreds to millions of single nucleotide polymorphisms (SNPs) into a score that can be used for genetic risk stratification. However, current PRS approaches only utilize the additive associations between SNPs and disease risk in a one-dimensional score. Here, we show that leveraging multiple types of genetic effects in multi-dimensional risk vectors, or a polygenic risk vector (PRV), can improve the stratification of cardio-metabolic diseases risks. Using data from UK Biobank (UKBB) and Electronic Medical Records and Genomics (eMERGE) Network biobank linked electronic health records (EHR) as development and evaluation data, we found that the combined effects between the additive PRS and the dominant PRS outperformed either one in terms of disease risk stratification, especially for the individuals in the high-risk group. Our results demonstrate that disease risks are likely to be influenced by multiple types of genetic effects, and PRV could utilize these effects for better risk stratification while retaining the simplicity of the PRS method.
BibTeX
@misc{li2022polygenic,
  author = {Ruowang Li and Xinyuan Zhang and Binglan Li and QiPing Feng and Leah C. Kottyan and Yuan Luo and Konrad Teodor Sawicki and Atlas Khan and Nita Limdi and Megan J. Puckelwartz and Wei‐Qi Wei and Chunhua Weng and Yong Chen and Marylyn D. Ritchie and Jason H. Moore},
  title = {{Polygenic risk vectors (PRV) improve genetic risk stratification for cardio-metabolic diseases}},
  year = {2022},
  doi = {10.1101/2022.03.02.22271425},
  howpublished = {medRxiv},
}
Figure